Publication Name	World Journal of Clinical Oncology
Manuscript ID	40267
Country	Singapore

Received	2018-06-11 09:41
Peer-Review Started	2018-06-12 00:17
To Make the First Decision	2018-07-19 07:45
Return for Revision	2018-07-23 03:02
Revised	2018-08-02 00:26
Second Decision	2018-08-06 09:53
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2018-08-07 05:01
Articles in Press	2018-08-07 05:01
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-09-10 03:20
Publish the Manuscript Online	2018-09-14 11:38

ISSN	2218-4333 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Minireviews
Article Title	Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies
Manuscript Source	Invited Manuscript
All Author List	Jianbiao Zhou and Wee-Joo Chng
ORCID	Author(s) ORCID Number Jianbiao Zhou http://orcid.org/0000-0002-5679-671X Wee-Joo Chng http://orcid.org/0000-0003-2578-8335
Funding Agency and Grant Number	Funding Agency Grant Number Singapore National Research Foundation to Chng WJ Ministry of Education under the Research Center of Excellence Program to Chng WJ NMRC Clinician-Scientist IRG Grant CNIG11nov38 (to Zhou J) NMRC Clinician Scientist Investigator award to Chng WJ RNA Biology Center at CSI Singapore, NUS, from funding by the Singapore Ministry of Education’s Tier 3 grants MOE2014-T3-1-006
Corresponding Author	Jianbiao Zhou, MD, PhD, Senior Scientist, Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, 28 Medical Drive, Singapore 119074, Singapore. csizjb@nus.edu.sg
Key Words	FMS-like tyrosine kinase 3; Tyrosine kinase domain; Internal tandem duplication; FLT3 inhibitor; Drug resistance; Acute myeloid leukemia; Combination therapy
Core Tip	FMS-like tyrosine kinase 3 (FLT3) mutations including internal tandem duplication (ITD) or point mutation in tyrosine kinase domain are common genetic abnormalities in acute myeloid leukemia (AML), predicting dismal outcome. The Federal Drug Administration granted the use of Midostaurin (Novartis) in newly diagnosed FLT3-ITD positive AML in April 2017. A number of other FLT3 inhibitors are in different phases of clinical trials. However, emerging drug resistance poses a major challenge for clinicians to use FLT3 inhibitors. In this manuscript, we systematically reviewed mechanism of primary resistance and acquired resistance to FLT3 inhibitors. We then propose different strategies to overcome drug resistance and novel treatment options for FLT3-ITD positive AML.
Publish Date	2018-09-14 11:38
Citation	Zhou J, Chng WJ. Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies. World J Clin Oncol 2018; 9(5): 90-97
URL	http://www.wjgnet.com/2218-4333/full/v9/i5/90.htm
DOI	http://dx.doi.org/10.5306/wjco.v9.i5.90

Full Article (PDF)	WJCO-9-90.pdf
Full Article (Word)	WJCO-9-90.doc
Manuscript File	40267-Review.doc
Answering Reviewers	40267-Answering reviewers.pdf
Audio Core Tip	40267-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	40267-Conflict-of-interest statement.pdf
Copyright License Agreement	40267-Copyright license agreement.pdf
Approved Grant Application Form(s) or Funding Agency Copy of any Approval Document(s)	40267-Grant application form(s).pdf
Non-Native Speakers of English Editing Certificate	40267-Language certificate.pdf
Peer-review Report	40267-Peer-review(s).pdf
Scientific Misconduct Check	40267-Scientific misconduct check.pdf
Scientific Editor Work List	40267-Scientific editor work list.pdf